344 related articles for article (PubMed ID: 34440739)
1. Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
Huang TH; Mokgautsi N; Huang YJ; Wu ATH; Huang HS
Cells; 2021 Aug; 10(8):. PubMed ID: 34440739
[TBL] [Abstract][Full Text] [Related]
2. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
3. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
[No Abstract] [Full Text] [Related]
4. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
[TBL] [Abstract][Full Text] [Related]
5. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
[TBL] [Abstract][Full Text] [Related]
7. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition.
Cheng XS; Li YF; Tan J; Sun B; Xiao YC; Fang XB; Zhang XF; Li Q; Dong JH; Li M; Qian HH; Yin ZF; Yang ZB
Cancer Lett; 2014 Jun; 348(1-2):77-87. PubMed ID: 24657657
[TBL] [Abstract][Full Text] [Related]
8. Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer.
Elbadawy M; Usui T; Yamawaki H; Sasaki K
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083525
[TBL] [Abstract][Full Text] [Related]
9. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.
Hwang WL; Yang MH; Tsai ML; Lan HY; Su SH; Chang SC; Teng HW; Yang SH; Lan YT; Chiou SH; Wang HW
Gastroenterology; 2011 Jul; 141(1):279-91, 291.e1-5. PubMed ID: 21640118
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.
Yang J; Cao C; Luo D; Lan S; Luo M; Shan H; Ma X; Liu Y; Yu S; Zhong X; Li R
Eur J Med Chem; 2020 Jul; 198():112336. PubMed ID: 32387836
[TBL] [Abstract][Full Text] [Related]
11. Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer.
Mokgautsi N; Kuo YC; Chen CH; Huang YJ; Wu ATH; Huang HS
Cells; 2023 Jan; 12(2):. PubMed ID: 36672275
[TBL] [Abstract][Full Text] [Related]
12. Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer.
Sato K; Masuda T; Hu Q; Tobo T; Gillaspie S; Niida A; Thornton M; Kuroda Y; Eguchi H; Nakagawa T; Asano K; Mimori K
EBioMedicine; 2019 Jun; 44():387-402. PubMed ID: 31175057
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer.
Yuan W; Ji J; Shu Y; Chen J; Liu S; Wu L; Zhou Z; Liu Z; Tang Q; Zhang X; Shu X
J Mol Med (Berl); 2019 Jan; 97(1):89-102. PubMed ID: 30460377
[TBL] [Abstract][Full Text] [Related]
14. BMAL1 promotes colorectal cancer cell migration and invasion through ERK- and JNK-dependent c-Myc expression.
Shan L; Zheng W; Bai B; Hu J; Lv Y; Chen K; Wang X; Pan Y; Huang X; Zhu H; Dai S
Cancer Med; 2023 Feb; 12(4):4472-4485. PubMed ID: 36806631
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
Liu C; Pan Z; Chen Q; Chen Z; Liu W; Wu L; Jiang M; Lin W; Zhang Y; Lin W; Zhou R; Zhao L
J Exp Clin Cancer Res; 2021 Sep; 40(1):297. PubMed ID: 34551797
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
[TBL] [Abstract][Full Text] [Related]
17. A pre-existing population of ZEB2
Francescangeli F; Contavalli P; De Angelis ML; Careccia S; Signore M; Haas TL; Salaris F; Baiocchi M; Boe A; Giuliani A; Tcheremenskaia O; Pagliuca A; Guardiola O; Minchiotti G; Colace L; Ciardi A; D'Andrea V; La Torre F; Medema J; De Maria R; Zeuner A
J Exp Clin Cancer Res; 2020 Jan; 39(1):2. PubMed ID: 31910865
[TBL] [Abstract][Full Text] [Related]
18. Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial-mesenchymal transition and colorectal cancer aggressiveness.
Franke FC; Slusarenko BO; Engleitner T; Johannes W; Laschinger M; Rad R; Nitsche U; Janssen KP
Int J Cancer; 2020 Sep; 147(6):1715-1731. PubMed ID: 32147820
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
20. The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer.
Zhu X; Li C; Gao Y; Zhang Q; Wang T; Zhou H; Bu F; Chen J; Mao X; He Y; Wu K; Li N; Luo H
J Exp Clin Cancer Res; 2024 Jan; 43(1):7. PubMed ID: 38163859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
